Deshpande Pallavi O, Mohan Vishwaraman, Thakurdesai Prasad Arvind
Department of Scientific Affairs, Indus Biotech Private Limited, Pune, Maharashtra, India.
Pharmacognosy Res. 2017 Apr-Jun;9(2):138-150. doi: 10.4103/0974-8490.204649.
To evaluate acute oral toxicity (AOT), subchronic (90-day repeated dose) toxicity, mutagenicity, and genotoxicity potential of IDM01, the botanical composition of 4-hydroxyisoleucine- and trigonelline-based standardized fenugreek ( L) seed extract in laboratory rats.
The AOT and subchronic (90-day repeated dose) toxicity were evaluated using Sprague-Dawley rats as per the Organisation for Economic Co-operation and Development (OECD) guidelines No. 423 and No. 408, respectively. During the subchronic study, the effects on body weight, food and water consumption, organ weights with hematology, clinical biochemistry, and histology were studied. The mutagenicity and genotoxicity of IDM01 were evaluated by reverse mutation assay (Ames test, OECD guideline No. 471) and chromosome aberration test (OECD guideline No. 473), respectively.
The IDM01 did not show mortality or treatment-related adverse signs during acute (limit dose of 2000 mg/kg) and subchronic (90-day repeated dose of 250, 500, and 1000 mg/kg with 28 days of recovery period) administration. The IDM01 showed oral median lethal dose (LD50) >2000 mg/kg during AOT study. The no-observed adverse effect level (NOAEL) of IDM01 was 500 mg/kg. IDM01 did not show mutagenicity up to a concentration of 5000 μg/plate during Ames test and did not induce structural chromosomal aberrations up to 50 mg/culture.
IDM01 was found safe during preclinical acute and subchronic (90-day repeated dose) toxicity in rats without mutagenicity or genotoxicity.
Acute oral toxicity, subchronic (90-day) oral toxicity, mutagenicity and genotoxicity of IDM01 (4-hydroxyisoleucine- and trigonelline-based standardized fenugreek seed extract) was evaluated.The median lethal dose, LD50, of IDM01 was more than 2000 mg/kg of body weight in rats.No observed adverse effect level (NOAEL) of IDM01 was 500 mg/kg of body weight in rats.IDM01 was found safe during acute and subchronic oral toxicity studies in rats without mutagenicity or genotoxicity potetial. 2-AA: 2-aminoanthracene; 2-AF: 2-aminofluorene; 4 NQNO: 4-nitroquinolene-N-oxide; 4HI: 4-hydroxyisoleucine; ANOVA: Analysis of variance; AOT: Acute oral toxicity; DM: Diabetes mellitus; IDM01: The Botanical composition of 4-hydroxyisoleucine- and trigonelline-based standardized fenugreek seed extract; LD50: Median lethal dose; MMS: Methyl methanesulfonate; NAD: No abnormality detected; OECD: Organisation for Economic Co-operation and Development; SD: Standard deviation; UV: Ultraviolet; VC: Vehicle control. 2-AA: 2-aminoanthracene; 2-AF: 2-aminofluorene; 4 NQNO: 4-nitroquinolene-N-oxide; 4HI: 4-hydroxyisoleucine; ANOVA: Analysis of variance; AOT: Acute oral toxicity; DM: Diabetes mellitus; IDM01: The Botanical composition of 4-hydroxyisoleucine- and trigonelline-based standardized fenugreek seed extract; LD50: Median lethal dose; MMS: Methyl methanesulfonate; NAD: No abnormality detected; OECD: Organisation for Economic Co-operation and Development; SD: Standard deviation; UV: Ultraviolet; VC: Vehicle control.
评估IDM01(一种基于4-羟基异亮氨酸和胡芦巴碱的标准化胡芦巴(L)种子提取物的植物成分)对实验大鼠的急性经口毒性(AOT)、亚慢性(90天重复给药)毒性、致突变性和遗传毒性。
分别按照经济合作与发展组织(OECD)第423号和第408号指南,使用斯普拉格-道利大鼠评估AOT和亚慢性(90天重复给药)毒性。在亚慢性研究期间,研究了对体重、食物和水消耗、器官重量以及血液学、临床生物化学和组织学的影响。分别通过回复突变试验(Ames试验,OECD第471号指南)和染色体畸变试验(OECD第473号指南)评估IDM01的致突变性和遗传毒性。
在急性(极限剂量2000 mg/kg)和亚慢性(90天重复剂量250、500和1000 mg/kg,恢复期28天)给药期间,IDM01未显示出死亡或与治疗相关的不良体征。在AOT研究中,IDM01的经口半数致死剂量(LD50)>2000 mg/kg。IDM01的未观察到不良影响水平(NOAEL)为500 mg/kg。在Ames试验中,IDM01在浓度高达5000 μg/平板时未显示出致突变性,在浓度高达50 mg/培养物时未诱导结构性染色体畸变。
在大鼠临床前急性和亚慢性(90天重复剂量)毒性研究中,发现IDM01安全,无致突变性或遗传毒性。
评估了IDM01(基于4-羟基异亮氨酸和胡芦巴碱的标准化胡芦巴种子提取物)的急性经口毒性、亚慢性(90天)经口毒性、致突变性和遗传毒性。IDM01在大鼠中的半数致死剂量LD50超过2000 mg/kg体重。IDM01在大鼠中的未观察到不良影响水平NOAEL为500 mg/kg体重。在大鼠急性和亚慢性经口毒性研究中,发现IDM01安全,无致突变性或遗传毒性潜力。2-AA:2-氨基蒽;2-AF:2-氨基芴;4-NQNO:4-硝基喹啉-N-氧化物;4HI:4-羟基异亮氨酸;ANOVA:方差分析;AOT:急性经口毒性;DM:糖尿病;IDM01:基于4-羟基异亮氨酸和胡芦巴碱的标准化胡芦巴种子提取物的植物成分;LD50:半数致死剂量;MMS:甲基磺酸甲酯;NAD:未检测到异常;OECD:经济合作与发展组织;SD:标准差;UV:紫外线;VC:溶剂对照。2-AA:2-氨基蒽;2-AF:2-氨基芴;4-NQNO:4-硝基喹啉-N-氧化物;4HI:4-羟基异亮氨酸;ANOVA:方差分析;AOT:急性经口毒性;DM:糖尿病;IDM01:基于4-羟基异亮氨酸和胡芦巴碱的标准化胡芦巴种子提取物的植物成分;LD50:半数致死剂量;MMS:甲基磺酸甲酯;NAD:未检测到异常;OECD:经济合作与发展组织;SD:标准差;UV:紫外线;VC:溶剂对照。